AnHeart and Innovent Announce Interim Data from Phase ? Trial (TRUST) of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
In the crizotinib treatment-naïve patient group (n=21), the confirmed objective response rate (ORR) was 90.5%…